Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Options In Face Of Merck’s Schering Bid Include OTC Deal

This article was originally published in The Tan Sheet

Executive Summary

One option for Johnson & Johnson in response to Merck's bid for Schering-Plough is to make a deal for the latter's consumer health business

You may also be interested in...



Merck Gives Consumer Health Care Division Direct Line To CEO

Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes

Merck Gives Consumer Health Care Division Direct Line To CEO

Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes

Merck Gives Consumer Health Care Division Direct Line To CEO

Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes

Related Content

Topics

UsernamePublicRestriction

Register

PS102710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel